Novartis announced today that it intends to separate Sandoz into a new, publicly traded standalone company through a 100% spinoff. The spinoff of the generics and biosimilars division of Novartis aims to maximize shareholder value by creating the top European generics company and a global leader in biosimilars, according to a news release. Such a…
Novartis mulls sale of $25 billion Sandoz generics arm
On the heels of announcing a restructuring plan that would do away with approximately 8,000 positions, Novartis AG (NYSE:NVS) is reportedly considering spinning off its Sandoz generics arm. The company is likely to make a final decision by the end of the year, according to Bloomberg. Given the sluggish state of the economy, Novartis is likely…
Novartis’ Sandoz, Ares Genetics seek better antibiotics deployment
Sandoz, a Novartis division, announced today that it extended and expanded a strategic collaboration agreement with Ares Genetics. Basel, Switzerland-baed Sandoz’s collaboration with Ares, aimed at driving innovation to develop solutions in the fight against antimicrobial resistance (AMR), was extended through January 31, 2025. According to a news release, the companies agreed to an extension…